Maravai LifeSciences Holdings, Inc..
MRVI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Maravai LifeSciences Holdings, Inc. is a life sciences company that provides critical products and services to enable the development of drug therapies, novel vaccines, and diagnostics. The company operates through two segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid ...Show More
Better Health for All
10
Maravai LifeSciences' core business is dedicated to enabling groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics, with 100% of its R&D and capital allocation focused on health improvement. Its CleanCap® technology was used in the first U.S. FDA-approved mRNA vaccine and three of four approved mRNA COVID-19 vaccines, impacting over 350 programs.
1
All 24 FDA- and EMA-approved CAR-T Cell and Gene Therapies utilize Cygnus Host Cell Protein ELISA kits for commercial product lot release, directly mitigating patient health risks from Host Cell Proteins.
2
During the COVID-19 pandemic, the company rapidly scaled production nine times in six months
3
and received $39 million from the U.S. Department of Defense for future pandemic preparedness.
4
The company maintains a strong safety record, with all manufacturing sites ISO 9001:2015 certified, Alphazyme ISO 13485 certified, and the TriLink facility meeting FDA GMP requirements.
5
Its 2023 OSHA Incident Rate was 0.3.
6
Maravai employs a multi-faceted approach to data protection, including an IT Steering Committee and third-party security firms.
7
It offers a 24/7 employee assistance program
8
and partners with Modern Health for mental health support, alongside external support for youth therapy services.
9
The company also supports extensive healthcare education initiatives, including STEM programs and university scholarships.
10
However, the Maravai LifeSciences Foundation's $300,000 donation in 2023 for health equity programs represented approximately 0.1% of the company's $289 million revenue.
11
External healthcare workforce support is limited to initiatives like two MLK Health Careers Scholarships.
12
The company's B2B model means direct price accessibility, vulnerable reach, and addiction mitigation are not applicable to its core products, nor are direct preventative health measures or clinical trial ethics.
Fair Money & Economic Opportunity
0
No evidence available to assess Maravai LifeSciences Holdings, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
40
For the fiscal year ended December 31, 2024, the estimated ratio of the Chief Executive Officer's annual total compensation to the median employee's annual total compensation was 48.1 to 1.
1
All full-time employees are eligible to participate in health and welfare benefit programs, including medical, dental, vision care, disability, and life insurance.
2
Additionally, all matching contributions to the 401(k) plan became fully vested for all employees starting January 1, 2024.
3
An organizational restructuring was announced on August 11, 2025, affecting approximately 25% of employees, with expected costs of $8.0 million to $9.0 million primarily for employee severance and benefits.
4
Fair Trade & Ethical Sourcing
0
The provided article explicitly states that it does not contain any data relevant to MRVI.US or the Fair Trade & Ethical Sourcing value.
1
Therefore, no specific evidence is available to score any of the KPIs in the rubric.
2
Honest & Fair Business
-20
Maravai LifeSciences has a formal whistleblower policy, effective November 24, 2020, which includes a 24/7/365 toll-free, confidential, and anonymous hotline operated by a third-party service provider.
1
The policy outlines investigation procedures and protection from retaliation.
2
All employees review and acknowledge the Code of Business Conduct and Ethics Policy annually and receive training during onboarding and annually thereafter.
3
However, the effectiveness of the program is not publicly measured. The company's anti-corruption policy is FCPA-compliant, and all employees annually review and acknowledge the Code of Business Conduct and Ethics Policy, receiving training during onboarding and annually thereafter.
4
There is no evidence of customized training for high-risk areas or third-party monitoring. 100% of manufacturing sites in operation in 2023 are certified to ISO 9001:2015 and audited annually for compliance.
5
This certification and audit cover quality management systems, but the percentage of total revenue, assets, or subsidiaries covered by independent external audit is not specified. Similarly, the ISO 9001:2015 certification and annual audits of manufacturing sites serve as independent verification for quality and compliance, but the extent of verification for broader ethical claims is not detailed.
Kind to Animals
70
Maravai LifeSciences and its operating units do not directly conduct any in vivo animal testing.
1
The company has not used animals in any testing protocols since 2010, and annual external audits confirm compliance. While the nucleic acid production business contracts with third-party research organizations to assess in vivo activity in animals, primarily mice, and the biologics safety testing business contracts with a facility for antibody production involving animal inoculation, these are not direct operations of Maravai.
2
No War, No Weapons
-10
Maravai LifeSciences states that its products do not contain or use 3TG minerals (tantalum, tin, tungsten, or gold) and it is not aware of any conflict minerals being sourced from the Democratic Republic of Congo or adjoining countries in its supply chain.
1
The company's Conflict Minerals Statement is available.
2
Maravai has a formal, publicly available Human Rights Policy that explicitly prohibits child labor and forced labor within its operations and supply chain, and this policy is informed by the United Nations Guiding Principles on Business and Human Rights.
3
The company has a Code of Business Conduct and Ethics and rolled out a new program with dedicated ethics liaisons at each company site.
4
Primary oversight of sustainability strategy and related risks is managed by the Nominating, Governance, and Risk (NGR) Committee of the Board of Directors.
5
The company's core business is life sciences, not defense, and no evidence of defense-related activities or controversial weapons exposure was found.
6
Planet-Friendly Business
-60
In 2024, the company's total Scope 1, 2, and 3 greenhouse gas emissions were 76,287.42 tCO₂e, an increase from 24,600.58 tCO₂e in 2023.
1
The company has committed to near-term science-based targets, but these targets have not been disclosed or validated by SBTi.
2
Maravai LifeSciences has committed to achieving net-zero emissions, but a specific target year has not been publicly disclosed.
3
The Leland, NC facility uses rooftop solar panels, which generated over 180,000 kWh in 2024, offsetting approximately 20% of that facility’s total energy consumption.
4
The company's total water withdrawal was 38.19 megaliters in 2024, with revenue of $259.2 million, resulting in 147.34 m³ per $1 million revenue.
5
In 2024, 83 MT of waste was recycled out of a total of 448 MT of waste generated, leading to an 18.53% waste diversion rate.
6
The company states that its operations comply in all material respects with applicable environmental laws and regulations and that capital and operating expenditures for pollution control were not material in 2023 and 2024, with no major violations reported.
7
Respect for Cultures & Communities
0
No specific, concrete data points were found across the provided articles to assess Maravai LifeSciences (MRVI.US) against the KPIs for 'Respect for Cultures & Communities'. The articles either explicitly state that data for these metrics is not applicable or not mentioned, or they focus on internal company operations and philanthropic activities of a foundation rather than direct community engagement or cultural impact metrics for MRVI.US.
Safe & Smart Tech
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to Safe & Smart Tech. While some articles mention general cybersecurity practices, they lack the quantitative data, specific incidents, or detailed policy information required to score against the rubric's thresholds. For example, the company states that past security incidents have not materially impacted it, but this is not specific enough to score data breach severity.
1
Similarly, while the company mentions using third-party consultants for vulnerability assessments and security testing,
2
and adhering to NIST and other global standards for security control principles,
3
there is no information on the scope, frequency, or effectiveness of these measures, nor any specific privacy certifications
4
or details on AI ethics governance
5
or investment in cybersecurity.
6
Compliance with SEC regulations is mentioned,
7
but not with specific privacy regulations like GDPR or CCPA, which are explicitly noted as not mentioned.
8
Zero Waste & Sustainable Products
-30
Maravai LifeSciences has not reported any waste disposal violations in the past three years.
1
The company recycles at all locations, manages hazardous waste, promotes reusable containers, recycles organic waste, and donates e-waste.
2
Additionally, Maravai uses biodegradable plastic bags for shipping and other processes at many sites and is planning for a lab plastics recycling program and single-use plastic phase-out.
3